Literature DB >> 6874004

Monoclonal antibodies to rat sarcomata. II. A syngeneic IgG2b antibody with anti-tumour activity.

S M North, C J Dean.   

Abstract

The IgG2b monoclonal antibody M10/76, which is specific for the Hooded rat fibrosarcoma MC24, was obtained by fusion of the rat myeloma Y3 Ag 1.2.3 with spleen cells from an MC24 tumour-bearing rat. This antibody has been found to inhibit lung colonization when MC24 cells were injected i.v. into Hooded rats, and when passively transferred into athymic MC24 tumour bearers, it prevented or considerably reduced the incidence of spontaneous lung metastases in more than half the treated animals.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6874004      PMCID: PMC1454322     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  13 in total

1.  The distribution and fate of blood-borne 125IUdR-labelled tumour cells in immune syngeneic rats.

Authors:  J W Proctor; B G Auclair; C M Rudenstam
Journal:  Int J Cancer       Date:  1976-08-15       Impact factor: 7.396

2.  The influence of host immunity on the arrest of circulating cancer cells, and its modification by neuraminidase.

Authors:  L Weiss; D Glaves; D A Waite
Journal:  Int J Cancer       Date:  1974-06-15       Impact factor: 7.396

3.  Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG.

Authors:  G Galfrè; C Milstein; B Wright
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

4.  Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: selection of low antigenic variants in vivo.

Authors:  W W Young; S I Hakomori
Journal:  Science       Date:  1981-01-30       Impact factor: 47.728

5.  Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.

Authors:  L M Nadler; P Stashenko; R Hardy; W D Kaplan; L N Button; D W Kufe; K H Antman; S F Schlossman
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

6.  Immunotherapy of murine leukemias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells.

Authors:  M E Kirch; U Hammerling
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

7.  Use of monoclonal antibodies as diagnostic and therapeutic reagents in acute lymphoblastic leukemia.

Authors:  J Ritz; J M Pesando; J Notis-McConarty; L A Clavell; S E Sallan; S F Schlossman
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

8.  Metastasis in the nude rat associated with lack of immune response.

Authors:  S A Eccles; J M Styles; S M Hobbs; C J Dean
Journal:  Br J Cancer       Date:  1979-11       Impact factor: 7.640

9.  Effect of cyclosporin A on the growth and spontaneous metastasis of syngeneic animal tumours.

Authors:  S A Eccles; S E Heckford; P Alexander
Journal:  Br J Cancer       Date:  1980-08       Impact factor: 7.640

10.  Influence of tumour growth on the evolution of cytotoxic lymphoid cells in rats bearing a spontaneously metastasizing syngeneic fibrosarcoma.

Authors:  G A Currie; J O Gage
Journal:  Br J Cancer       Date:  1973-08       Impact factor: 7.640

View more
  4 in total

1.  A receptor for monomeric IgG2b on rat macrophages.

Authors:  S Denham; R Barfoot; E Jackson
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

2.  Regulation of serum antibodies induced in syngeneic rats after administration of monoclonal antibody MT10:21.

Authors:  S M North; J L Gurin
Journal:  Immunology       Date:  1989-01       Impact factor: 7.397

3.  Growth inhibition of experimental glioma grafts by monoclonal antibody treatment.

Authors:  D Stavrou; W Mellert; U Mellert; E Keiditsch; K Bise; P Mehraein
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

4.  The production of hybridomas from the gut associated lymphoid tissue of tumour bearing rats. I. Mesenteric nodes as a source of IgG producing cells.

Authors:  C J Dean; J M Styles; L A Gyure; J Peppard; S M Hobbs; E Jackson; J G Hall
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.